HFG
MCID: HND003
MIFTS: 50

Hand-Foot-Uterus Syndrome (HFG) malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Bone diseases, Fetal diseases

Aliases & Classifications for Hand-Foot-Uterus Syndrome

Aliases & Descriptions for Hand-Foot-Uterus Syndrome:

Name: Hand-Foot-Uterus Syndrome 54 12 24 25 56 66 13
Hand-Foot-Genital Syndrome 54 12 23 24 25 56 66 52 14
Hfgs 12 23 50 24 25 56
Hfg Syndrome 23 50 24 25 66
Hand Foot Uterus Syndrome 50 29 69
Hfu Syndrome 50 25 66
Hand Foot Genital Syndrome 50
Urogenital Abnormalities 42
Hfu 66
Hfg 66

Characteristics:

Orphanet epidemiological data:

56
hand-foot-genital syndrome
Inheritance: Autosomal dominant;

GeneReviews:

23
hand-foot-uterus syndrome:
Inheritance autosomal dominant inheritance


GeneReviews:

23
Penetrance Skeletal defects are 100% penetrant...

Classifications:



External Ids:

OMIM 54 140000
Disease Ontology 12 DOID:0060739
ICD10 33 Q51.2
Orphanet 56 ORPHA2438
ICD10 via Orphanet 34 Q51.2
UMLS via Orphanet 70 C1841679
MedGen 40 C1841679

Summaries for Hand-Foot-Uterus Syndrome

Genetics Home Reference : 25 Hand-foot-genital syndrome is a rare condition that affects the development of the hands and feet, the urinary tract, and the reproductive system. People with this condition have abnormally short thumbs and first (big) toes, small fifth fingers that curve inward (clinodactyly), short feet, and fusion or delayed hardening of bones in the wrists and ankles. The other bones in the arms and legs are normal.

MalaCards based summary : Hand-Foot-Uterus Syndrome, also known as hand-foot-genital syndrome, is related to guttmacher syndrome and schimmelpenning-feuerstein-mims syndrome, somatic mosaic, and has symptoms including microtia, strabismus and abnormal dermatoglyphics. An important gene associated with Hand-Foot-Uterus Syndrome is HOXA13 (Homeobox A13). The drugs Cyproterone Acetate and Drospirenone have been mentioned in the context of this disorder. Affiliated tissues include uterus and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and limbs/digits/tail

Disease Ontology : 12 A autosomal dominant disease characterized by distal limb defects (short thumbs and first toes, clinodactyly of the fifth fingers, delayed ossification of the wrist and ankle bones), urogenital defects and that has material basis in heterozygous mutation in the HOXA13 gene on chromosome 7p15.

UniProtKB/Swiss-Prot : 66 Hand-foot-genital syndrome: A disorder characterized by limb and genitourinary anomalies. Clinical features include small feet with unusually short great toes and abnormal thumbs. Females with the disorder have duplication of the genital tract.

Wikipedia : 71 Hand-foot-genital syndrome (HFGS) is characterized by limb malformations and urogenital defects. Mild... more...

Description from OMIM: 140000
GeneReviews: NBK1423

Related Diseases for Hand-Foot-Uterus Syndrome

Graphical network of the top 20 diseases related to Hand-Foot-Uterus Syndrome:



Diseases related to Hand-Foot-Uterus Syndrome

Symptoms & Phenotypes for Hand-Foot-Uterus Syndrome

Symptoms by clinical synopsis from OMIM:

140000

Clinical features from OMIM:

140000

Human phenotypes related to Hand-Foot-Uterus Syndrome:

56 32 (show all 39)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 microtia 56 32 Occasional (29-5%) HP:0008551
2 strabismus 56 32 Occasional (29-5%) HP:0000486
3 abnormal dermatoglyphics 56 32 Frequent (79-30%) HP:0007477
4 hypospadias 56 32 Frequent (79-30%) HP:0000047
5 clinodactyly of the 5th finger 56 32 Frequent (79-30%) HP:0004209
6 vesicoureteral reflux 56 32 Frequent (79-30%) HP:0000076
7 ventricular septal defect 56 32 Occasional (29-5%) HP:0001629
8 recurrent urinary tract infections 56 32 Frequent (79-30%) HP:0000010
9 sacral dimple 56 32 Occasional (29-5%) HP:0000960
10 short distal phalanx of finger 56 32 Very frequent (99-80%) HP:0009882
11 short hallux 56 32 Very frequent (99-80%) HP:0010109
12 synostosis of carpal bones 56 32 Very frequent (99-80%) HP:0005048
13 proximal placement of thumb 56 32 Very frequent (99-80%) HP:0009623
14 ureteropelvic junction obstruction 56 32 Very frequent (99-80%) HP:0000074
15 postaxial hand polydactyly 56 32 Occasional (29-5%) HP:0001162
16 short 1st metacarpal 56 32 Very frequent (99-80%) HP:0010034
17 hypoplastic fifth toenail 56 32 Frequent (79-30%) HP:0011937
18 bicornuate uterus 56 32 Very frequent (99-80%) HP:0000813
19 spontaneous abortion 56 32 Occasional (29-5%) HP:0005268
20 shortening of all middle phalanges of the fingers 56 32 Very frequent (99-80%) HP:0006110
21 hallux varus 56 32 Frequent (79-30%) HP:0008080
22 short first metatarsal 56 32 Very frequent (99-80%) HP:0010105
23 renal insufficiency 32 HP:0000083
24 brachydactyly syndrome 32 HP:0001156
25 abnormality of the uterus 56 Very frequent (99-80%)
26 abnormality of the urethra 56 Frequent (79-30%)
27 bifid scrotum 32 HP:0000048
28 micropenis 32 HP:0000054
29 uterus didelphys 32 HP:0003762
30 short 5th finger 32 HP:0009237
31 short thumb 56 Very frequent (99-80%)
32 short 2nd toe 32 HP:0001885
33 chordee 32 HP:0000041
34 small thenar eminence 32 HP:0001245
35 delayed ossification of carpal bones 32 HP:0001216
36 ulnar deviation of the 2nd finger 32 HP:0009464
37 delayed tarsal ossification 32 HP:0008103
38 longitudinal vaginal septum 32 HP:0008740
39 pseudoepiphyses 32 HP:0010584

GenomeRNAi Phenotypes related to Hand-Foot-Uterus Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.6 HOXD13
2 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.6 HOXD13
3 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.6 HOXA13
4 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.6 HOXA13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.6 DLX6 HOXA13 HOXD13
6 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.6 HOXA13
7 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.6 HOXA13
8 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.6 HOXD13
9 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.6 HOXD13
10 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.6 HOXD13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.6 HOXA13
12 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.6 DLX6
13 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.6 HOXD13
14 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.6 DLX6
15 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.6 HOXD13
16 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.6 HOXD13
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 DLX6
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.43 HOXD13
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.43 HOXA13
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-195 9.43 HOXA13
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.43 HOXA13
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.43 HOXA13 HOXD13

MGI Mouse Phenotypes related to Hand-Foot-Uterus Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 limbs/digits/tail MP:0005371 9.65 DLX6 HOXA11 HOXA13 HOXD10 HOXD13
2 renal/urinary system MP:0005367 9.46 HOXA11 HOXA13 HOXD10 HOXD13
3 reproductive system MP:0005389 9.26 HOXA11 HOXA13 HOXD10 HOXD13
4 skeleton MP:0005390 9.02 DLX6 HOXA11 HOXA13 HOXD10 HOXD13

Drugs & Therapeutics for Hand-Foot-Uterus Syndrome

Drugs for Hand-Foot-Uterus Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 423)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
2
Drospirenone Approved Phase 4 67392-87-4 68873
3
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
4
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
5
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 57-83-0 5994
6
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
7
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
8
Zinc Approved Phase 4 7440-66-6 32051 23994
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Sevoflurane Approved, Vet_approved Phase 4,Phase 2 28523-86-6 5206
11
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
12
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
13
Ethanol Approved Phase 4,Phase 2 64-17-5 702
14
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
15
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2 76631-46-4, 113775-47-6 68602 5311068 56032
17
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
18
Menotropins Approved Phase 4 61489-71-2 5360545
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1 58-05-9 54575, 6560146 143
21 Androgen Antagonists Phase 4,Phase 2,Phase 1
22 Androgens Phase 4,Phase 3,Phase 2,Phase 1
23 Antioxidants Phase 4,Phase 3,Phase 2
24 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Contraceptive Agents, Male Phase 4,Phase 3
26 Contraceptives, Oral Phase 4,Phase 3,Phase 2
27 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2
28
Cyproterone Phase 4 2098-66-0 5284537
29 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
30 diuretics Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Drospirenone and ethinyl estradiol combination Phase 4
33 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
34 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1
35 Estradiol valerate Phase 4,Phase 3,Phase 2,Phase 1 979-32-8
36 Estrogens Phase 4,Phase 3,Phase 2,Phase 1
37 Hemostatics Phase 4
38 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
41 Mineralocorticoid Receptor Antagonists Phase 4
42 Mineralocorticoids Phase 4,Phase 2
43 Natriuretic Agents Phase 4
44 Polyestradiol phosphate Phase 4,Phase 3,Phase 2,Phase 1
45 Protective Agents Phase 4,Phase 3,Phase 2,Early Phase 1
46 Vitamin B Complex Phase 4,Phase 2,Phase 1
47 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
48 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
50 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 454)
id Name Status NCT ID Phase
1 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4
2 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4
3 Pudendal Block Versus Caudal Block for Hypospadias Completed NCT02390388 Phase 4
4 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4
5 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4
6 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4
7 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4
8 A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone Completed NCT00097552 Phase 4
9 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
10 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4
11 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4
12 Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD) Completed NCT00097526 Phase 4
13 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
14 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
15 The Effect of Induction Technique on Postoperative Pain and Agitation Completed NCT02110745 Phase 4
16 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4
17 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4
18 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
19 Taste, Smell and Chemotherapy (TASTY) Completed NCT01641172 Phase 4
20 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
21 Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants? Recruiting NCT02861950 Phase 4
22 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Recruiting NCT02880280 Phase 4
23 Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Recruiting NCT02408445 Phase 4
24 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Recruiting NCT03015909 Phase 4
25 Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery Not yet recruiting NCT02848157 Phase 4
26 Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature Terminated NCT00121875 Phase 4
27 Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients Terminated NCT01073644 Phase 4
28 A Clinical Study to Assess the Efficacy and Safety of DA-3002 Unknown status NCT01813630 Phase 3
29 Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair Completed NCT02752308 Phase 2, Phase 3
30 Dexmedetomidine Infusion in Hypospadias Surgery Completed NCT00926705 Phase 3
31 An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG Completed NCT00250250 Phase 3
32 Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Completed NCT01710696 Phase 3
33 Use of Somatropin in Turner Syndrome Completed NCT01518036 Phase 3
34 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Completed NCT00406926 Phase 3
35 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3
36 The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Completed NCT00029159 Phase 3
37 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed NCT00234533 Phase 3
38 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome Completed NCT00140998 Phase 3
39 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3
40 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3
41 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3
42 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3
43 Diindolylmethane in Treating Patients With Abnormal Cervical Cells Completed NCT00462813 Phase 3
44 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed NCT00678392 Phase 3
45 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed NCT01057810 Phase 3
46 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer Completed NCT01204749 Phase 3
47 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3
48 Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer Completed NCT00744497 Phase 3
49 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Recruiting NCT03062280 Phase 3
50 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Recruiting NCT02716818 Phase 3

Search NIH Clinical Center for Hand-Foot-Uterus Syndrome

Cochrane evidence based reviews: urogenital abnormalities

Genetic Tests for Hand-Foot-Uterus Syndrome

Genetic tests related to Hand-Foot-Uterus Syndrome:

id Genetic test Affiliating Genes
1 Hand Foot Uterus Syndrome 29
2 Hand-Foot-Genital Syndrome 24 HOXA13

Anatomical Context for Hand-Foot-Uterus Syndrome

MalaCards organs/tissues related to Hand-Foot-Uterus Syndrome:

39
Uterus, Bone

Publications for Hand-Foot-Uterus Syndrome

Articles related to Hand-Foot-Uterus Syndrome:

id Title Authors Year
1
The hand-foot-genital (hand-foot-uterus) syndrome: family report and update. ( 3189398 )
1988
2
The hand-foot-uterus syndrome: a case study. ( 3772265 )
1986
3
Radiographic findings in the hand-foot-uterus syndrome (HFUS). ( 5417032 )
1970
4
Hand-foot-uterus syndrome. ( 4179869 )
1969

Variations for Hand-Foot-Uterus Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Hand-Foot-Uterus Syndrome:

66
id Symbol AA change Variation ID SNP ID
1 HOXA13 p.Asn372His VAR_017776 rs121912542
2 HOXA13 p.Ile368Phe VAR_075341
3 HOXA13 p.Val375Phe VAR_075342

ClinVar genetic disease variations for Hand-Foot-Uterus Syndrome:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HOXA13 NM_000522.4(HOXA13): c.1107G> A (p.Trp369Ter) single nucleotide variant Pathogenic rs104894019 GRCh37 Chromosome 7, 27237877: 27237877
2 HOXA13 HOXA13, 407A-C single nucleotide variant Pathogenic
3 HOXA13 HOXA13, 24-BP INS, 8-ALA EXP insertion Pathogenic
4 HOXA13 NM_000522.4(HOXA13): c.1114A> C (p.Asn372His) single nucleotide variant Pathogenic rs121912542 GRCh37 Chromosome 7, 27237870: 27237870
5 HOXA13 HOXA13, 18-BP INS, 6-ALA EXP insertion Pathogenic
6 HOXA13 HOXA13, 27-BP INS, 9-ALA EXP insertion Pathogenic
7 HOXA13 NM_000522.4(HOXA13): c.355_406dup52 (p.Ser136Cysfs) duplication Pathogenic rs387906542 GRCh37 Chromosome 7, 27239291: 27239342

Expression for Hand-Foot-Uterus Syndrome

Search GEO for disease gene expression data for Hand-Foot-Uterus Syndrome.

Pathways for Hand-Foot-Uterus Syndrome

GO Terms for Hand-Foot-Uterus Syndrome

Biological processes related to Hand-Foot-Uterus Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.77 DLX6 HOXA11 HOXA13 HOXD10 HOXD13
2 multicellular organism development GO:0007275 9.65 DLX6 HOXA11 HOXA13 HOXD10 HOXD13
3 single fertilization GO:0007338 9.43 HOXA11 HOXD10
4 embryonic digit morphogenesis GO:0042733 9.4 HOXA11 HOXD13
5 anterior/posterior pattern specification GO:0009952 9.33 HOXA11 HOXD10 HOXD13
6 proximal/distal pattern formation GO:0009954 9.32 HOXA11 HOXD10
7 embryonic limb morphogenesis GO:0030326 9.26 DLX6 HOXA11 HOXD10 HOXD13
8 skeletal system development GO:0001501 9.02 DLX6 HOXA11 HOXA13 HOXD10 HOXD13

Molecular functions related to Hand-Foot-Uterus Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.35 DLX6 HOXA11 HOXA13 HOXD10 HOXD13
2 sequence-specific DNA binding GO:0043565 9.02 DLX6 HOXA11 HOXA13 HOXD10 HOXD13

Sources for Hand-Foot-Uterus Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....